LMR Partners LLP Reduces Stock Holdings in Ascendis Pharma A/S (NASDAQ:ASND)

LMR Partners LLP lowered its holdings in shares of Ascendis Pharma A/S (NASDAQ:ASND) by 22.5% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 3,100 shares of the biotechnology company’s stock after selling 900 shares during the quarter. LMR Partners LLP’s holdings in Ascendis Pharma A/S were worth $463,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also recently made changes to their positions in ASND. Price T Rowe Associates Inc. MD increased its holdings in Ascendis Pharma A/S by 23.3% during the first quarter. Price T Rowe Associates Inc. MD now owns 1,781,926 shares of the biotechnology company’s stock valued at $269,374,000 after buying an additional 336,976 shares during the last quarter. Avoro Capital Advisors LLC increased its stake in shares of Ascendis Pharma A/S by 5.8% in the 2nd quarter. Avoro Capital Advisors LLC now owns 4,196,661 shares of the biotechnology company’s stock worth $572,341,000 after purchasing an additional 229,995 shares in the last quarter. Fred Alger Management LLC raised its holdings in Ascendis Pharma A/S by 65.0% in the 2nd quarter. Fred Alger Management LLC now owns 307,073 shares of the biotechnology company’s stock worth $41,879,000 after purchasing an additional 120,952 shares during the period. Tri Locum Partners LP lifted its position in Ascendis Pharma A/S by 102.1% during the second quarter. Tri Locum Partners LP now owns 227,762 shares of the biotechnology company’s stock valued at $31,062,000 after purchasing an additional 115,092 shares in the last quarter. Finally, Farallon Capital Management LLC bought a new stake in Ascendis Pharma A/S during the first quarter valued at about $16,478,000.

Wall Street Analysts Forecast Growth

ASND has been the topic of several recent research reports. JPMorgan Chase & Co. decreased their price objective on Ascendis Pharma A/S from $180.00 to $174.00 and set an “overweight” rating on the stock in a research note on Wednesday, October 23rd. TD Cowen lowered their price target on shares of Ascendis Pharma A/S from $160.00 to $153.00 and set a “buy” rating on the stock in a report on Friday, November 15th. Cantor Fitzgerald reissued an “overweight” rating and issued a $170.00 price objective on shares of Ascendis Pharma A/S in a research note on Friday, November 15th. Oppenheimer decreased their price objective on shares of Ascendis Pharma A/S from $190.00 to $180.00 and set an “outperform” rating on the stock in a research report on Friday, November 15th. Finally, Stifel Nicolaus upped their target price on shares of Ascendis Pharma A/S from $200.00 to $207.00 and gave the stock a “buy” rating in a report on Friday, November 15th. Two investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $191.77.

Ascendis Pharma A/S Stock Up 2.0 %

Shares of Ascendis Pharma A/S stock opened at $124.44 on Wednesday. The firm has a market cap of $7.55 billion, a price-to-earnings ratio of -15.40 and a beta of 0.66. Ascendis Pharma A/S has a twelve month low of $90.13 and a twelve month high of $161.00. The business has a 50-day moving average price of $132.59 and a 200-day moving average price of $132.38.

Ascendis Pharma A/S (NASDAQ:ASND) last released its quarterly earnings results on Tuesday, September 3rd. The biotechnology company reported ($2.05) earnings per share for the quarter, missing the consensus estimate of ($1.54) by ($0.51). The business had revenue of $38.75 million during the quarter, compared to analyst estimates of $94.74 million. On average, equities analysts expect that Ascendis Pharma A/S will post -7.3 EPS for the current fiscal year.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.